Search | Clinical Trials Finder

Conditions: Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 28
States / cities: Birmingham, Alabama • Sherman Oaks, California • Temecula, California + 21 more

Conditions: Major Depressive Disorder
Interventions: Antidepressant + Placebo, Antidepressant + Aripiprazole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 20
States / cities: Garden Grove, California • Northridge, California • Washington D.C., District of Columbia + 17 more

Conditions: Depressive Disorder, Major
Interventions: LY2216684 (edivoxetine), SSRI; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 21 more

Conditions: Depressive Disorder, Major, Anhedonia
Interventions: Aticaprant, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 39
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo, SSRI; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 27
States / cities: Redlands, California • Sherman Oaks, California • Wildomar, California + 24 more

Conditions: Major Depression Disorder
Interventions: Adjunct brexpiprazole, ADT; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 65 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: Arcadia, California • Miami, Florida • Orlando, Florida + 9 more

Conditions: Major Depressive Disorder
Interventions: OPC-34712, Placebo, ADT; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 50
States / cities: Arcadia, California • Beverly Hills, California • Escondido, California + 43 more

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Aripiprazole, Placebo Capsule, Placebo Tablet; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Adjunctive Treatment of Major Depressive Disorder
Interventions: Pimavanserin, Placebo; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 41
States / cities: Birmingham, Alabama • Garden Grove, California • Glendale, California + 34 more

Conditions: Refractory Major Depressive Disorder
Interventions: ALKS 5461; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 29
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Alamitos, California + 26 more

Conditions: Major Depressive Disorder
Interventions: Auricular Acupuncture, Sham Auricular Acupuncture + Lexapro; Device · Drug
Lead sponsor: Florida Gulf Coast University; Other
Eligibility: 18 Years to 24 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Depressive Disorder, Major
Interventions: Aticaprant; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 871 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 87
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 70 more

Conditions: Major Depressive Disorder (MDD)
Interventions: ADT, Brexpiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 24
States / cities: Garden Grove, California • Temecula, California • Orlando, Florida + 21 more

Conditions: Depressive Disorder, Major
Interventions: Rapastinel, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 31
States / cities: Beverly Hills, California • Costa Mesa, California • Encino, California + 28 more

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: Brexpiprazole, Seroquel XR, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more

Conditions: Depressive Disorder, Major
Interventions: Rapastinel; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 128
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 104 more

Conditions: Major Depressive Disorder
Interventions: mixed salts amphetamine; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: Placebo + ADT, Brexpiprazole +ADT; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 837 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 30
States / cities: Birmingham, Alabama • Beverly Hills, California • Denver, Colorado + 27 more

Conditions: Major Depressive Disorder, Irritability
Interventions: Brexpiprazole; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 15
States / cities: Tucson, Arizona • Glendale, California • Oakland, California + 12 more

Conditions: Depressive Disorder, Major
Interventions: Ropinirole CR; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Stanford, California

Conditions: Adjunctive Treatment of Major Depressive Disorder
Interventions: CLE-100, placebo; Drug
Lead sponsor: Clexio Biosciences Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 45
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more

Conditions: Major Depressive Disorder
Interventions: ALKS 5461, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Colton, California • Garden Grove, California + 29 more

Conditions: Major Depressive Disorder
Interventions: NBI-1065845, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Huntsville, Alabama • Glendale, California • Irvine, California + 7 more

Search by objective public record fields.

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

A Safety Study in Participants With Major Depressive Disorder

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

A Study in Prevention of Re-emergence of Depression Symptoms

Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)

Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy

Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression

A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)